Entrada Therapeutics (TRDA) Insider Trading & Ownership $6.26 -0.12 (-1.88%) Closing price 04:00 PM EasternExtended Trading$6.27 +0.01 (+0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Entrada Therapeutics (NASDAQ:TRDA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.11%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$2.79M Get TRDA Insider Trade Alerts Want to know when executives and insiders are buying or selling Entrada Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TRDA Insider Buying and Selling by Quarter Entrada Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/9/2025Kush ParmarDirectorSell27,000$7.50$202,500.00 7/9/2025Ventures V L.P. 5AmMajor ShareholderSell20,065$7.50$150,487.50 7/9/2025Ventures V L.P. 5AmMajor ShareholderSell6,935$7.50$52,012.50 6/30/2025Kush ParmarDirectorSell25,000$6.81$170,250.00 6/30/2025Ventures V L.P. 5AmMajor ShareholderSell18,578$6.81$126,516.18 6/30/2025Ventures V L.P. 5AmMajor ShareholderSell6,422$6.81$43,733.82 6/27/2025Kush ParmarDirectorSell75,000$6.91$518,250.00 6/27/2025Ventures V L.P. 5AmMajor ShareholderSell55,735$6.91$385,128.85 6/27/2025Ventures V L.P. 5AmMajor ShareholderSell19,265$6.91$133,121.15 12/10/2024Bioventures 2018 L.P. MpmMajor ShareholderSell22,935$20.77$476,359.95 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/2/2024Kory James WentworthCFOSell5,000$20.00$100,000.00 11/29/2024Kory James WentworthCFOSell1,000$19.97$19,970.00 11/13/2024Natarajan SethuramanInsiderSell2,700$20.04$54,108.00 11/11/2024Kory James WentworthCFOSell8,637$19.98$172,567.26 11/11/2024Natarajan SethuramanInsiderSell1,409$20.01$28,194.09 10/16/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00 9/26/2024Nathan J DowdenCOOSell847$16.00$13,552.00 9/9/2024Kory James WentworthCFOSell3,195$14.97$47,829.15 9/9/2024Natarajan SethuramanInsiderSell2,642$15.09$39,867.78 9/9/2024Nathan J DowdenCOOSell1,904$15.07$28,693.28 9/6/2024Natarajan SethuramanInsiderSell600$15.24$9,144.00 9/6/2024Nathan J DowdenCOOSell399$15.19$6,060.81 (Data available from 1/1/2013 forward) TRDA Insider Trading Activity - Frequently Asked Questions Who is on Entrada Therapeutics' Insider Roster? The list of insiders at Entrada Therapeutics includes Bioventures 2018 L.P. Mpm, Dipal Doshi, Kory James Wentworth, Kush Parmar, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher, Peter S Kim, and Ventures V L.P. 5Am. Learn more on insiders at TRDA. What percentage of Entrada Therapeutics stock is owned by insiders? 8.11% of Entrada Therapeutics stock is owned by insiders. Learn more on TRDA's insider holdings. Which Entrada Therapeutics insiders have been buying company stock? The following insider purchased TRDA shares in the last 24 months: Peter S Kim ($151,226.80). How much insider buying is happening at Entrada Therapeutics? Insiders have purchased a total of 11,172 TRDA shares in the last 24 months for a total of $151,226.80 bought. Which Entrada Therapeutics insiders have been selling company stock? The following insiders have sold TRDA shares in the last 24 months: Bioventures 2018 L.P. Mpm ($476,359.95), Dipal Doshi ($184,956.00), Kory James Wentworth ($541,153.63), Kush Parmar ($891,000.00), Natarajan Sethuraman ($326,361.12), Nathan J Dowden ($61,398.93), Nerissa Kreher ($266,748.00), and Ventures V L.P. 5Am ($891,000.00). How much insider selling is happening at Entrada Therapeutics? Insiders have sold a total of 361,599 Entrada Therapeutics shares in the last 24 months for a total of $3,638,977.63 sold. Entrada Therapeutics Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Compensation: $968.21kMr. Nathan J. Dowden (Age 53)President & COO Compensation: $694.3kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Compensation: $694.3kMr. Kory James Wentworth CPA (Age 45)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory Affairs More Insider Trading Tools from MarketBeat Related Companies Amphastar Pharmaceuticals Insider Trades WAVE Life Sciences Insider Trades Aurinia Pharmaceuticals Insider Trades Ardelyx Insider Trades Enliven Therapeutics Insider Trades Verve Therapeutics Insider Trades Dyne Therapeutics Insider Trades Cidara Therapeutics Insider Trades Collegium Pharmaceutical Insider Trades Nurix Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional SupportDo They Know Something? Insiders & Congress Buy UnitedHealth This page (NASDAQ:TRDA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
